Abstract: Systems, apparatuses, and methods are provided for planning, activating, analyzing, and monitoring clinical trials. A planning process gathers clinical trial initiation parameters and produces a clinical trial plan. An activation process prepares and activates clinical sites in various countries to screen, enroll, and provide clinical trial drugs or devices to subjects. An analysis process tracks the rate at which trial completion objectives are completed and models progress scenarios (e.g., best case, worst case, base, etc.) and potential outcomes. Finally, a monitoring process allows a clinical trial manager to monitor the progress of the clinical trial and modify the clinical trial plan as needed to meet trial completion objectives.

Abstract: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.

Abstract: A syringe and filter cap ease the administration of medication to patients. The cap fits securely over the syringe nozzle and has at least one orifice. The orifice is configured to retain medication particles within the syringe, while allowing liquid to be drawn into the syringe through the cap. A kit combines the medication, the syringe and its plunger, the cap, and a liquid holder cup. The method of administering the medication entails: (a) removing the plunger from the syringe, (b) placing the cap over the nozzle, (c) inserting the particulate medication into the syringe, (d) re-inserting the plunger into the syringe, (e) drawing the desired amount of liquid into the syringe through the cap, thereby suspending the particulate medication within the liquid drawn into the syringe, (f) removing the cap from the syringe, and (g) delivering the medication dosage to the patient.

Abstract: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.

Abstract: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or<3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or<2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or<2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or<1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.

Abstract: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate; a second phase of two groups of daily dosage units, which consist of a first group containing 5 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 2 mg of dienogest, and a second group containing 17 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily dosage units each consisting of 1 mg of estradiol valerate; and another phase of 2 daily dosage units of a pharmaceutically harmless placebo; so that the multiphase combination preparation consists of a total number of 28 daily dosage units.